key: cord-0761747-0trra374 authors: He, Ruyuan; Lu, Zilong; Zhang, Lin; Fan, Tao; Xiong, Rui; Shen, Xiaokang; Feng, Haojie; Meng, Heng; Lin, Weichen; Jiang, Wenyang; Geng, Qing title: The clinical course and its correlated immune status in COVID-19 pneumonia date: 2020-04-12 journal: J Clin Virol DOI: 10.1016/j.jcv.2020.104361 sha: 95ba3972c9555480c0bf1331ba384d109d676067 doc_id: 761747 cord_uid: 0trra374 Abstract Objectives To explore the clinical course and its dynamic features of immune status in COVID-19 patients and find predictors correlated with severity and prognosis of COVID-19. Methods The electronic medical records of 204 patients with COVID-19 pneumonia confirmed by nucleic acid testing were retrospectively collected and analyzed. Results All Patients were divided into severe (69) and non-severe group (135). Lymphocyte subsets count, including CD3 + T cell, CD4 + T cell, CD8 + T cell, B cell (CD19+) and NK cell (CD16 + 56+), were significantly lower in severe group (P＜0.001). The dynamic levels of T lymphocytes in severe group were significantly lower from disease onset, but in the improved subgroup the value of T lymphocyte began to increase after about 15-day treatment and finally returned to the normal level. The cut-off value of the counts of CD3+ (576), CD4+ (391) and CD8+ (214) T cell were calculated and indicated significantly high sensitivity and specificity for severity of COVID-19. Conclusion Our results shown that the decrease of CD3+, CD4+ and CD8 + T lymphocyte correlated with the course of patients with COVID-19 pneumonia, especially in severe cases. The level of T lymphocyte could be used as an indicator for prediction of severity and prognosis of patients with COVID-19 pneumonia. The application of glucocorticoid should be cautious in severe cases. In December 2019, the acute viral respiratory diseases named as Coronavirus disease 2019 (COVID-19) was reported in Wuhan, China. COVID-19 is caused by a novel Coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The World Health Organization (WHO) has listed the novel coronavirus pneumonia epidemic as a public health emergency of international concern. As of April 1, 2020, over 700,000 SARS-CoV-2 infection had been confirmed all over the world. The clinical presentation of COVID-19 varies from mild to severe, but most elder patients or patients with known comorbidities, such as hypertension, diabetes, cardiomyopathy, chronic renal failure, chronic obstructive pulmonary disease (COPD) and decreased immunity appear to be at a higher risk of developing severe disease, resulting in a high case-fatality rate 1,2 . A retrospective study showed the mortality is 61.5% in severe patients with COVID-19 3 . Early identification and intervention for the underlying severe patients was crucial for reduction of mortality. Due to the lack of specific antiviral drugs and vaccine, own immune status become one of the most crucial factors affecting disease progression and prognosis. The clinical laboratory data of patients revealed that most COVID-19 cases displayed significant low circulating lymphocyte counts, especially severe patients admitted to ICU 1,2,4 . We aimed to characterize the immune status between the severe and non-severe patients with COVID-19 pneumonia, review the correlation of the clinical course and dynamic changes of T lymphocyte subsets in those patients, and attempt to find an indicator for early identification of the underlying severe patients with COVID-19 pneumonia. This is a retrospective study. All patients were enrolled confirmed by fluorescence reversetranscriptase-polymerase chain reaction (fRT-PCR) assay for SARS-CoV-2 in Renmin Hospital of Wuhan University between January 10.2020 and February 13,2020. All patients were divided into severe and non-severe group according to "Pneumonia diagnosis and treatment program for novel coronavirus infection (trial version 5)" issued by National Health Commission of the People's Republic of China (http://www.nhc.gov.cn/). The clinical classification was summarized as Table S1 . The end of follow-up is February 13, 2020. The electronic medical records, including the epidemiological, clinical, laboratory, and radiological findings of patients were collected and analyzed. The laboratory results were obtained within the early stage of the disease. The cases with incomplete data were excluded. Statistical analysis was performed using SPSS 23.0 software and GraphPad prism 8.0 software. Percentages and frequency rates were used to describe categorical variables, mean, median, interquartile range (IQR) and standard deviation (SD) were used to describe continue variables. T test or Mann-Whitney test were used to compare mean for continuous variables. A total of 204 patients were enrolled in the study. The median age of 204 patients were 49 (IQR, 34-62), and 79 (38.73%) patients were male. There were 57 (57, 27.94%) patients with comorbidities, including hypertension, diabetes, malignancy, chronic lung disease and other diseases. The clinical manifestation of COVID-19 pneumonia was listed in Table 1 Patients were divided into non-severe (135, 66.18%) and severe group (69, 33.82%). There was significant difference of age between non-severe (43, IQR, 31-53) and severe (61, IQR, 52-74) group. Compared to non-severe patients, comorbidities, including hypertension, cardiovascular diseases and cerebral aneurysm, were significantly higher in severe group. The proportion of patients with dyspnea (68.12%) was also significant higher in severe group. Chest CT was the important method of diagnosis for COVID-19 pneumonia. There was significant difference between non-severe and severe group. The bilateral and multiple lobe lesions were seen in the most patients with COVID-19 (all P＜0.01). Significant difference in laboratory findings were observed between non-severe and severe group (Table 2) Patients also were divided into age ＜ 60 and age ≥ 60 group. There were significant differences in count of lymphocyte subsets between two groups (Fig S1, a) . Compared to patients without comorbidities, the count of T lymphocyte and value of humoral immune, such as IgM, IgA and C4, were significant lower in patients with comorbidities ( Fig S1, g, j). The results shown that the level of all lymphocyte subsets was normal during hospitalization in non-severe groups (Fig 1) . The level of T lymphocytes was significant lower in patients of COVID-19 pneumonia in severe group (Fig 1 a, As of February 13, 134 (65.69%) patients were discharged, 44 (21.57%) patients were hospitalization and 26 (12.75%) patients were dead. Our results have indicated that the level of lymphocyte subsets was strongly correlated with the course of COVID-19 patients. ROC curve and area under ROC curve (AUC) were used to assess the diagnostic value of them for identification of severe COVID-19. Our results shown that the count of CD3 + , CD4 + and CD8 + T cell had significantly high sensitivity and specificity (Fig 1, f) pneumonia. Simultaneously, the cut-off value was calculated according to ROC curve, including CD3 + T cell (576), CD4 + T cell (391), CD8 + T cell (214), B cell (111) and NK cell (128). The sensitivity and specificity of humoral immune parameters were not excellent and the AUC of them were at the range from 0.5 to 0.612 and lower than AUC of T lymphocytes (Fig 1, g) . In addition, our results shown that the cut-off value of T lymphocytes can excellently identify the severe and non-severe groups in 29 patients with dynamic data. The 7 patients in severe group improved and transformed into non-severe type after 20-day treatment, and the cut-off value of T lymphocytes also excellently predicted the dynamic trends of diseases. J o u r n a l P r e -p r o o f SARS-CoV-2 has high infectivity and pathogenicity. The basic reproductive number R0 of SARS-Cov-2 was estimated to be 3.77, much higher than SARS-CoV(R0=2.7) and MERS-CoV (R0＜1) [5] [6] [7] . The affinity between SARS-CoV-2 and ACE2 receptor is 10-20 times higher than that of SARS-CoV 8 . Without a therapeutic vaccine or specific antiviral drugs, early detection and intervention for the underlying severe patients was crucial for reduction of mortality. Consistent with previous studies 1,2 , the average age of patients and its comorbidities in severe group were significantly higher than those in non-severe group. The distribution of gender was significantly different between two groups. In severe groups, the mortality of male patients was higher, suggesting that the male patient may be more tend to develop into severe illness. The epidemiological data from CCDC also indicated that the mortality of male patients was higher than the female. The sex-based immunological differences also contribute to variations in the susceptibility to infectious diseases and responses to virus 9 . There were significant increases of white blood cell and neutrophil, decrease of lymphocyte in severe patients, which were consistent with other COVID-19 studies. The further analysis about lymphocyte subsets also indicated that the count of all lymphocyte subsets significantly declined in severe patients than those in non-severe group. CD3 as the biomarker of mature T lymphocyte, helps to activate the CD4 + T cell and CD8 + T cell 10 . CD4 + T cell and CD8 + T cell have an important role in regulating and maintaining the stability of the internal immune environment 11 . Some research about SARS shown that a dramatic loss of CD4 + T (90-100% of patients) and CD8 + T cells (80-90% patients) was characterized in patients with the acute phase of SARS 12 . The mechanism of the reduction of T lymphocytes may be associated with the direct invasion of SRAS-COV-2, which have been confirmed in MERS-CoV 13 and dendritic cell (DC) cells, and SARS-CoV-2 may alter function of APC and impair DC migration, which can reduce priming of T lymphocytes 16, 17 . In addition to being affected by SARS-CoV-2 and other immune cell, the function of T lymphocytes was also regulated by cytokines. TNF-α is a pro-inflammatory cytokine which can promote T lymphocytes apoptosis through interacting with TNFR1, which mainly expressed on aged T cell 18 immunologically active cells such as macrophages and B lymphocytes 20 . The complement system was a critical part of host defense to many bacterial, viral, and fungal infections. But the complement system was also strictly regulated through a number of inhibiting proteins in the serum, because of its potential to damage host tissues 21 . Our results shown that complement C3 were significantly higher in severe patients with COVID-19 pneumonia than that in non-severe patients. It had been found that complement activation The results of ROC curve further confirmed that the levels of CD3 + , CD4 + and CD8 + T cell performed excellent sensitivity and specificity for severity of COVID-19. The cut-off value of T lymphocytes also excellently predicted the dynamic trends of diseases, facilitate to detect and intervene the underlying severe patients earlier, which was crucial for reduction of mortality. The results of our study also provided some new perspectives for treatment of severe COVID-19. Glucocorticoids which can suppress cell-mediated immunity, promote the decrease of T lymphocyte and delay the virus clearance 24 , may aggravate the impaired function of T lymphocytes in patients with SARS-CoV-2. Therefore, the use of glucocorticoid should be cautious in severe patients with COVID-19 pneumonia, and the timing of glucocorticoid application deserves further exploration. Improvement of T lymphocytes function maybe a promising therapy for severe patients with COVID-19 pneumonia. The study was a retrospective analysis and was approved by the Ethics Committee of Renmin Hospital of Wuhan University (approved number: WDRY2020-K009) The authors declare no conflict of interest. Clinical features of patients infected with The Lancet Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China Interhuman transmissibility of Middle East respiratory syndrome coronavirus: estimation of pandemic risk. The Lancet Transmission Dynamics of the Etiological Agent of SARS in Hong Kong: Impact of Public Health Interventions Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation Sex differences in immune responses Structural basis of assembly of the human T cell receptor-CD3 complex Adaptive immune responses to primary and secondary dengue virus infections Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis Middle East Respiratory Syndrome Coronavirus Efficiently Infects Human Primary T Lymphocytes and Activates the Extrinsic and Intrinsic Apoptosis Pathways Hematological findings in SARS patients and possible mechanisms (Review) Human immunopathogenesis of severe acute respiratory syndrome (SARS) Severe Acute Respiratory Syndrome (SARS) Coronavirus-Induced Lung Epithelial Cytokines Exacerbate SARS Pathogenesis by Modulating Intrinsic Functions of Monocyte-Derived Macrophages and Dendritic Cells Evasion by Stealth: Inefficient Immune Activation Underlies Poor T Cell Response and Severe Disease Increased TNF-α-Induced Apoptosis in Lymphocytes from Aged Humans: Changes in TNF-α Receptor Expression and Activation of Caspases IL-4 production by group 2 innate lymphoid cells promotes food allergy by blocking regulatory T-cell function T cell-mediated immune response to respiratory coronaviruses Complement System Part I -Molecular Mechanisms of Activation and Regulation Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis The role of C5a in acute lung injury induced by highly pathogenic viral infections Immune regulation by glucocorticoids Lymphocyte subpopulation CD3 count Cytokines (28) c IL-2, pg/ml The number of patients whose data of Hypersensitive troponin I was available were 86, including 37 non-severe patients and 49 severe patients. b. The number of patients whose data of humoral immune function was available were 189, including 125 non-severe patients and 64 severe patients. c. The number of patients whose data of cytokines was available were 28 We acknowledge health-care workers involved in the diagnosis and treatment of COVID-19 and all patients in our study.